Literature DB >> 12370802

The role of prenylated small GTP-binding proteins in the regulation of osteoclast function.

F P Coxon1, M J Rogers.   

Abstract

The Ras superfamily of small GTP-binding proteins (also known as small GTPases) comprises more than 80 highly conserved proteins of the Ras, Rho, and Rab subfamilies that are involved in multiple intracellular signalling pathways. These proteins are able to function as molecular switches in the transduction of signals from membrane receptors by cycling between an inactive, GDP-bound state and an active, GTP-bound state, which can then interact with a number of different effector molecules (Fig. 1). The activity of small GTPases is regulated by three classes of regulatory proteins: guanine nucleotide exchange factors (GEFs), which catalyse the exchange of GDP for GTP, thereby activating the small GTPase; GTPase-activating proteins (GAPs), which enhance the intrinsic ability of small GTPases to hydrolyse GTP, resulting in reversion to the inactive GDP-bound state; and guanine nucleotide dissociation inhibitors (GDIs), which preferentially bind to the GDP-bound GTPases in the cytoplasm, thereby inhibiting the release of GDP and maintaining the GTPase in the inactive state [1]. GDIs have not been identified for all small GTPases, but play an important role in the control of the Rho family GTPases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370802     DOI: 10.1007/s00223-002-2017-2

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  25 in total

1.  Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption.

Authors:  Nathan J Pavlos; Jiake Xu; Dietmar Riedel; Joyce S G Yeoh; Steven L Teitelbaum; John M Papadimitriou; Reinhard Jahn; F Patrick Ross; Ming H Zheng
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

Review 2.  Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength.

Authors:  Meghan E McGee-Lawrence; Hannah V Carey; Seth W Donahue
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-08       Impact factor: 3.619

3.  Genome-wide association identifies three new susceptibility loci for Paget's disease of bone.

Authors:  Omar M E Albagha; Sachin E Wani; Micaela R Visconti; Nerea Alonso; Kirsteen Goodman; Maria Luisa Brandi; Tim Cundy; Pui Yan Jenny Chung; Rosemary Dargie; Jean-Pierre Devogelaer; Alberto Falchetti; William D Fraser; Luigi Gennari; Fernando Gianfrancesco; Michael J Hooper; Wim Van Hul; Gianluca Isaia; Geoff C Nicholson; Ranuccio Nuti; Socrates Papapoulos; Javier del Pino Montes; Thomas Ratajczak; Sarah L Rea; Domenico Rendina; Rogelio Gonzalez-Sarmiento; Marco Di Stefano; Lynley C Ward; John P Walsh; Stuart H Ralston
Journal:  Nat Genet       Date:  2011-05-29       Impact factor: 38.330

4.  Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

Authors:  Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2011-07-31       Impact factor: 1.895

Review 5.  Bisphosphonates pathway.

Authors:  Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2011-01       Impact factor: 2.089

Review 6.  Bone-targeted agents in the treatment of lung cancer.

Authors:  Shobha C Silva; Caroline Wilson; Penella J Woll
Journal:  Ther Adv Med Oncol       Date:  2015-07       Impact factor: 8.168

7.  Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.

Authors:  Jacqueline E Reilly; Jeffrey D Neighbors; Huaxiang Tong; Michael D Henry; Raymond J Hohl
Journal:  Clin Exp Metastasis       Date:  2015-06-13       Impact factor: 5.150

8.  Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.

Authors:  Luigi Sinigaglia; Massimo Varenna; Silvia Casari
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

Review 9.  Should we abandon statins in the prevention of bone fractures?

Authors:  Katherine Esposito; Annalisa Capuano; Liberata Sportiello; Andrea Giustina; Dario Giugliano
Journal:  Endocrine       Date:  2013-03-24       Impact factor: 3.633

Review 10.  Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.

Authors:  Solomon Epstein
Journal:  Curr Osteoporos Rep       Date:  2006-03       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.